Dr. Reddy's Laboratories Limited (NYSE: RDY) was downgraded by analysts at StockNews.com from a "strong-buy" rating to a "buy" rating.
Pulmonary Arterial Hypertension Drugs Market to Grow by USD 2.26 Billion from 2024-2028, as Rising PAH Prevalence Drives Demand with AI Redefining Market Landscape - Technavio [Yahoo! Finance]
Dr. Reddy's Q2 Earnings Miss Estimates, Global Generics Revenues Grow [Yahoo! Finance]
Dr. Reddy's Laboratories Limited (NYSE: RDY) had its price target lowered by analysts at Barclays PLC from $17.40 to $17.00. They now have an "overweight" rating on the stock.
Dr Reddy's Laboratories Ltd (RDY) (HY 2025) Earnings Call Highlights: Strong Revenue Growth and ... [Yahoo! Finance]